MetaCap

Innoviva Inc. (INVA)

NASDAQ: INVAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

18.410.00 (0.00%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

INVA stock chart

Technical analysis

Key statistics

All statistics
Ex-dividend date
Sep 8, 2015
52-week range
18.19 – 25.15
Day range
18.33 – 18.79
Volume / Avg
1.15M / 865.66K
Beta
—

52-week range

$18.19$25.15

INVA stock today

Innoviva (INVA) closed at $18.41 on Nov 20, essentially unchanged from the prior close, versus the S&P 500's 3.70% decline. At this level, INVA sits near the bottom of its 52-week range of $18.19 to $25.15: 26.8% below the high, set on Feb 26, 2026 and 1.2% above the low. INVA is down 7.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 12.2%.

Innoviva trades at 7.8x its trailing twelve-month earnings per share of $2.35. Its forward P/E of 8.3x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Innoviva

Company profile

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Pavel Raifeld C.F.A.
Headquarters
Burlingame, CA
Employees
159
IPO year
2004
Website
inva.com

Financial highlights

Full financials

In fiscal 2025, Innoviva generated $411.3 million in revenue, up 14.7% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $271.2 million (+1059.2% year over year), for a net margin of 65.9% versus a median of 66.5% in the prior 5 years. Gross margin was 74.8% (down from 82.6%) and operating margin 39.8%.

Innoviva annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$411.33M$358.71M$310.46M$331.34M$391.87M
Growth+14.67%+15.54%-6.30%-15.45%+16.35%
Net income$271.17M$23.39M$179.72M$220.26M$368.84M
EPS (diluted)$3.30$0.36$2.20$2.37$2.87

Analyst forecast

Forecast

Consensus (5 analysts)

buy

Avg. price target

$34.80+89.03%

  • Strong buy 0
  • Buy 4
  • Hold 0
  • Sell 1
  • Strong sell 0

Target range

Low $18.00High $46.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-1.03 vs $0.49
Surprise
-310.20%

Dividends

Dividend history
Annual dividend
$0.00
Last payment
$0.25
Ex-dividend date
Sep 8, 2015

INVA news

All INVA news

Innoviva peers

Health Care sector
INVA peer companies
CompanyPrice% ChgMarket capCompare
NUVBNuvation Bio Inc. Class A3.80-0.26%$1.34Bvs INVA
NBTXNanobiotix S.A. ADR26.50-2.98%$1.35Bvs INVA
PAHCPhibro Animal Health Corporation Class A33.29-2.32%$1.35Bvs INVA
AVLNAvalyn Pharma Inc.28.40-1.05%$1.26Bvs INVA
URGNUroGen Pharma Ltd.27.65-12.86%$1.36Bvs INVA
QUREuniQure N.V.19.35-4.35%$1.36Bvs INVA
LBRXLB Pharmaceuticals Inc38.85-2.97%$1.26Bvs INVA
RAPPRapport Therapeutics Inc.23.16-1.82%$1.37Bvs INVA

Indexes, lists and sector

Innoviva stock FAQ

What is Innoviva's stock price today?

INVA last traded at $18.41 as of Nov 20, 4:00 PM EST, up 0.00% on the day. Prices are delayed at least 15 minutes.

Does Innoviva pay a dividend?

Yes. Innoviva pays $0.00 per share annually. The most recent dividend of $0.25 had an ex-dividend date of Sep 8, 2015.

What is INVA's P/E ratio?

INVA trades at a trailing P/E ratio of 7.83 and a forward P/E of 8.33.

Who is Innoviva's CEO?

Mr. Pavel Raifeld C.F.A. is the chief executive officer of Innoviva Inc., which has about 159 employees.

Has INVA ever split its stock?

Yes. The most recent INVA stock split was a 1241-for-1000 split on Jun 3, 2014.

What is the INVA 52-week high?

The 52-week high for INVA is $25.15 and the 52-week low is $18.19. The stock is currently 26.8% below its high.

Compare INVA